US Broker Ratings

ICU Medical (ICUI) Stock Analysis: A 19.61% Upside Awaits Investors in the Healthcare Sector

ICU Medical, Inc. (NASDAQ: ICUI), a prominent player in the healthcare sector, has captured investor attention with its potential 19.61% upside, as indicated by analyst ratings. With a market capitalization..

Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis: A 19.42% Potential Upside in the CNS Market

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) is capturing the attention of investors with its strategic focus on central nervous system (CNS) diseases, a sector poised for significant growth. Headquartered in Rockville,..

CRISPR Therapeutics AG (CRSP)

⚠️ No article content returned.

..

Disc Medicine, Inc. (IRON) Stock Analysis: Exploring a 54.50% Upside in the Biotech Sector

In the dynamic landscape of biotechnology, Disc Medicine, Inc. (NASDAQ: IRON) emerges as a promising player, garnering significant attention from investors. With a market capitalization of $2.98 billion, this clinical-stage..

Denali Therapeutics Inc. (DNLI) Stock Analysis: Exploring an 83% Upside Potential

For investors keen on the biotechnology sector, Denali Therapeutics Inc. (NASDAQ: DNLI) presents a compelling opportunity with a noteworthy 83% potential upside. Specializing in treatments for neurodegenerative and lysosomal storage..

AtriCure, Inc. (ATRC) Investor Outlook: Analyzing a 40% Potential Upside

AtriCure, Inc. (NASDAQ: ATRC), a prominent player in the healthcare sector, specifically in the medical instruments and supplies industry, continues to capture investor attention with its innovative cardiac and surgical..

National HealthCare Corporation (NHC) Stock Analysis: A Stable Player in the Healthcare Sector with 12.5% Revenue Growth

National HealthCare Corporation (NYSE: NHC), a key player in the healthcare sector, has made a notable impact with its steady revenue growth and robust financial health. The company is positioned..

Ascentage Pharma Group Internat (AAPG): Investor Outlook on a Potential 61% Upside in Biotech Innovation

Ascentage Pharma Group International (AAPG), a clinical-stage biotechnology company based in China, is generating buzz among investors with a promising potential upside of 61.08%. Specializing in developing therapies for cancers,..

GRAIL, Inc. (GRAL) Stock Analysis: Navigating the Healthcare Frontier with Strong Revenue Growth

GRAIL, Inc. (NASDAQ: GRAL) stands out in the healthcare sector with its cutting-edge diagnostics and research services, focusing on revolutionizing cancer detection through its innovative testing solutions. The company, headquartered..

Teladoc Health, Inc. (TDOC) Stock Analysis: Navigating Challenges with a 25% Potential Upside

Teladoc Health, Inc. (NYSE: TDOC), a pioneer in the virtual healthcare space, has been at the forefront of transforming how individuals access medical services. As the healthcare industry continues its..

Ardent Health, Inc. (ARDT) Stock Analysis: Exploring the 50% Potential Upside

Ardent Health, Inc. (NASDAQ: ARDT), a prominent player in the healthcare sector, presents a compelling investment opportunity, boasting a market capitalization of $1.27 billion. Headquartered in Brentwood, Tennessee, Ardent operates..

Celldex Therapeutics, Inc. (CLDX) Stock Analysis: Unpacking a 107.86% Potential Upside in Biotech Innovation

Celldex Therapeutics, Inc. (NASDAQ: CLDX), a prominent player in the biotechnology sector, has recently caught the attention of investors with its impressive potential upside of 107.86%. As a biopharmaceutical company..

Schrodinger, Inc. (SDGR) Stock Analysis: Is a 34% Upside Within Reach?

Investors seeking opportunities in the healthcare sector might find Schrodinger, Inc. (NASDAQ: SDGR) an intriguing prospect. With its roots in the health information services industry, Schrodinger is making waves with..

Metsera, Inc. (MTSR) Stock Analysis: Navigating a 19.15% Downside Amidst Biotech’s Intriguing Developments

Metsera, Inc. (MTSR), a clinical-stage biotechnology company, has been capturing attention with its focus on innovative treatments for obesity and related metabolic disorders. As a subsidiary of Pfizer Inc., Metsera..

ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis: A 153% Potential Upside Sparks Investor Interest

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a promising player in the biotechnology sector, has recently caught the attention of investors due to its remarkable potential upside of 153.37%. Headquartered in San..

Azenta, Inc. (AZTA) Stock Analysis: Exploring a 15.88% Upside Potential in the Healthcare Sector

For investors keen on tapping into the dynamic healthcare sector, Azenta, Inc. (NASDAQ: AZTA) presents an intriguing opportunity. With its focus on providing cutting-edge sample management and multiomics solutions, Azenta..

Alphatec Holdings, Inc. (ATEC) Stock Analysis: Strong Buy Ratings and 41.69% Potential Upside Propel Investor Interest

Alphatec Holdings, Inc. (NASDAQ: ATEC), a key player in the healthcare sector and a prominent name in the medical devices industry, has been capturing investor attention with its innovative solutions..

Galapagos NV (GLPG) Stock Analysis: Why Investors Should Watch Despite a Challenging Outlook

Galapagos NV (NASDAQ: GLPG), a Belgian biotechnology company, stands out in the sector with its focus on developing innovative treatments in oncology and immunology. With a market capitalization of $2.18..

GoodRx Holdings, Inc. (GDRX) Stock Analysis: Exploring a 64.56% Potential Upside for Investors

GoodRx Holdings, Inc. (NASDAQ: GDRX) stands as a pivotal player in the U.S. healthcare sector, offering innovative solutions to help consumers save on prescription drug purchases. With a market capitalization..

Veracyte, Inc. (VCYT) Stock Analysis: A Diagnostics Leader with a 10.93% Upside Potential

Veracyte, Inc. (VCYT), a significant player in the healthcare sector, is making waves with its innovative approach to diagnostics and research. Headquartered in South San Francisco, this company focuses on..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds